183 related articles for article (PubMed ID: 36330204)
1. Downregulation of MCF2L Promoted the Ferroptosis of Hepatocellular Carcinoma Cells through PI3K/mTOR Pathway in a RhoA/Rac1 Dependent Manner.
Huang SC; Chen YM; Hu YY; Shi YJ; Xiao QW; Li Z; Kang JL; Zhou Q; Shen G; Jia HY
Dis Markers; 2022; 2022():6138941. PubMed ID: 36330204
[TBL] [Abstract][Full Text] [Related]
2. Glycyrrhizic acid attenuates sorafenib resistance by inducing ferroptosis via targeting mTOR signaling in hepatocellular carcinoma.
Hu Y; Luo Z; Cai S; Xie Q; Zheng S
Scand J Gastroenterol; 2024 Jun; 59(6):730-736. PubMed ID: 38426342
[TBL] [Abstract][Full Text] [Related]
3. CPLX2 Regulates Ferroptosis and Apoptosis Through NRF2 Pathway in Human Hepatocellular Carcinoma Cells.
Li H; Zhao J; Zhong XL; Xu PY; Du LJ; Fang P; Tan LJ; Li MJ; Zhang CF; Cao TS
Appl Biochem Biotechnol; 2023 Jan; 195(1):597-609. PubMed ID: 36107387
[TBL] [Abstract][Full Text] [Related]
4. Tiliroside targets TBK1 to induce ferroptosis and sensitize hepatocellular carcinoma to sorafenib.
Yang C; Lu T; Liu M; Yuan X; Li D; Zhang J; Zhou L; Xu M
Phytomedicine; 2023 Mar; 111():154668. PubMed ID: 36657316
[TBL] [Abstract][Full Text] [Related]
5. SPARC regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma.
Hua HW; Jiang HS; Jia L; Jia YP; Yao YL; Chen YW; Jiang F; Lu DQ; Zhou Q; Jiang MW; Ding G
Cancer Biomark; 2021; 32(4):425-433. PubMed ID: 33843664
[TBL] [Abstract][Full Text] [Related]
6. BEZ235 Increases the Sensitivity of Hepatocellular Carcinoma to Sorafenib by Inhibiting PI3K/AKT/mTOR and Inducing Autophagy.
Cao W; Liu X; Zhang Y; Li A; Xie Y; Zhou S; Song L; Xu R; Ma Y; Cai S; Tang X
Biomed Res Int; 2021; 2021():5556306. PubMed ID: 33987439
[TBL] [Abstract][Full Text] [Related]
7. CISD2 Promotes Resistance to Sorafenib-Induced Ferroptosis by Regulating Autophagy in Hepatocellular Carcinoma.
Li B; Wei S; Yang L; Peng X; Ma Y; Wu B; Fan Q; Yang S; Li X; Jin H; Tang S; Huang M; Li H; Liu J
Front Oncol; 2021; 11():657723. PubMed ID: 34485112
[TBL] [Abstract][Full Text] [Related]
8. TEA Domain Transcription Factor 1 Inhibits Ferroptosis and Sorafenib Sensitivity of Hepatocellular Carcinoma Cells.
Li H; Lan H; Zhang M; Zhao F; An N; Yi C
Dig Dis Sci; 2023 Jul; 68(7):3070-3082. PubMed ID: 36680650
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib induces mitochondrial dysfunction and exhibits synergistic effect with cysteine depletion by promoting HCC cells ferroptosis.
Li Y; Xia J; Shao F; Zhou Y; Yu J; Wu H; Du J; Ren X
Biochem Biophys Res Commun; 2021 Jan; 534():877-884. PubMed ID: 33162029
[TBL] [Abstract][Full Text] [Related]
10. Coptisine induces autophagic cell death through down-regulation of PI3K/Akt/mTOR signaling pathway and up-regulation of ROS-mediated mitochondrial dysfunction in hepatocellular carcinoma Hep3B cells.
Kim SY; Hwangbo H; Kim MY; Ji SY; Lee H; Kim GY; Kwon CY; Leem SH; Hong SH; Cheong J; Choi YH
Arch Biochem Biophys; 2021 Jan; 697():108688. PubMed ID: 33227289
[TBL] [Abstract][Full Text] [Related]
11. Macropinocytosis is an alternative pathway of cysteine acquisition and mitigates sorafenib-induced ferroptosis in hepatocellular carcinoma.
Byun JK; Lee S; Kang GW; Lee YR; Park SY; Song IS; Yun JW; Lee J; Choi YK; Park KG
J Exp Clin Cancer Res; 2022 Mar; 41(1):98. PubMed ID: 35287706
[TBL] [Abstract][Full Text] [Related]
12. TIMP1 represses sorafenib-triggered ferroptosis in colorectal cancer cells by activating the PI3K/Akt signaling pathway.
Wang L; Wang J; Chen L
Immunopharmacol Immunotoxicol; 2023 Dec; 45(4):419-425. PubMed ID: 36541209
[TBL] [Abstract][Full Text] [Related]
13. Sigma-1 receptor protects against ferroptosis in hepatocellular carcinoma cells.
Bai T; Lei P; Zhou H; Liang R; Zhu R; Wang W; Zhou L; Sun Y
J Cell Mol Med; 2019 Nov; 23(11):7349-7359. PubMed ID: 31507082
[TBL] [Abstract][Full Text] [Related]
14. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Koch A; Evers BM
Anticancer Res; 2010 Dec; 30(12):4951-8. PubMed ID: 21187475
[TBL] [Abstract][Full Text] [Related]
15. ABCC5 facilitates the acquired resistance of sorafenib through the inhibition of SLC7A11-induced ferroptosis in hepatocellular carcinoma.
Huang W; Chen K; Lu Y; Zhang D; Cheng Y; Li L; Huang W; He G; Liao H; Cai L; Tang Y; Zhao L; Pan M
Neoplasia; 2021 Dec; 23(12):1227-1239. PubMed ID: 34768109
[TBL] [Abstract][Full Text] [Related]
16. The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment.
Gedaly R; Angulo P; Chen C; Creasy KT; Spear BT; Hundley J; Daily MF; Shah M; Evers BM
Anticancer Res; 2012 Jul; 32(7):2531-6. PubMed ID: 22753710
[TBL] [Abstract][Full Text] [Related]
17. Camptothecin Sensitizes Hepatocellular Carcinoma Cells to Sorafenib- Induced Ferroptosis Via Suppression of Nrf2.
Elkateb AS; Nofal S; Ali SA; Atya HB
Inflammation; 2023 Aug; 46(4):1493-1511. PubMed ID: 37171695
[TBL] [Abstract][Full Text] [Related]
18. C2-ceramide enhances sorafenib-induced caspase-dependent apoptosis via PI3K/AKT/mTOR and Erk signaling pathways in HCC cells.
Jiang S; Wang Q; Feng M; Li J; Guan Z; An D; Dong M; Peng Y; Kuerban K; Ye L
Appl Microbiol Biotechnol; 2017 Feb; 101(4):1535-1546. PubMed ID: 27807662
[TBL] [Abstract][Full Text] [Related]
19. Synergistic antitumor effect of BRMS1 and sorafenib via inhibition of the PI3K/AKT/mTOR/ERK signaling pathway.
Jin J; Guo Y; Liu Y; Wang Z; Yang X; Sun S
Oncol Rep; 2019 Sep; 42(3):1183-1193. PubMed ID: 31233204
[TBL] [Abstract][Full Text] [Related]
20. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
